FIELD: medicine.
SUBSTANCE: invention relates to immunology. Proposed is a recombinant antibody consisting of two single-domain VHH antibodies specific for TNF, containing the TNF and glycoprotein CD11b specificity domain, containing a myeloid CD11b immune cell marker specificity domain, connected together by a protein linker.
EFFECT: decreased antibody size by 2 and ability to block TNF on human myeloid cells, including monocytes and granulocytes, and be expressed in a bacterial system in a soluble form.
1 cl, 5 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| RECOMBINANT SINGLE-DOMAIN ANTIBODY ABLE TO BIND HUMAN TUMOUR NECROSIS FACTOR SPECIFICALLY AND ITS DERIVATIVES | 2012 |
|
RU2530553C2 |
| TRISPECIFIC IL-17A, IL-17F AND OTHER PROINFLAMMATORY MOLECULES ANTIBODIES | 2016 |
|
RU2680011C2 |
| SELECTIVE BIFUNCTIONAL DRUG ON THE BASIS OF FRAGMENTS OF CAMEL SINGLE-CHAIN ANTIBODIES, AIMED ON TUMOR RECEPTORS CD47/CD44, INTENDED FOR THERAPY OF MALIGNANT NEOPLASMS | 2016 |
|
RU2658764C1 |
| RECOMBINANT SINGLE-DOMAIN ANTIBODIES SPECIFICALLY BINDING F4/80 PROTEIN, METHOD FOR PRODUCTION THEREOF AND USE FOR DETECTION OF SAID PROTEIN | 2015 |
|
RU2599423C1 |
| SELECTIVE BIFUNCTIONAL DRUG ON THE BASIS OF FRAGMENTS OF CAMELIZED SINGLE-CHAIN ANTIBODIES, AIMED TO ONCOTIC RECEPTORS CD47/ERBB2, INTENDED FOR THE THERAPY OF MALIGNANT NEOPLASMS | 2016 |
|
RU2648164C1 |
| METHODS AND ANTIBODIES FOR IMMUNE RESPONSE MODULATION | 2016 |
|
RU2757489C2 |
| SINGLE-DOMAIN ANTIBODY AND DERIVATIVES THEREOF TO LIGAND-1 PROTEIN OF PROGRAMMED CELL DEATH (PDLI) | 2016 |
|
RU2715595C2 |
| BISPECIFIC ANTI-HER2 / ANTI-HER3 ANTIBODIES | 2016 |
|
RU2653443C2 |
| CANCER TREATMENT WITH CHIMERIC CD33 ANTIGEN RECEPTOR | 2015 |
|
RU2747384C2 |
| HIGH AFFINITY AND AGGREGATIONALLY STABLE ANTIBODIES BASED ON VL VARIABLE DOMAINS AND VHH DERIVATIVE | 2014 |
|
RU2609627C2 |
